Andy Jones
Contributor since: 2020
ADMA Biologics' 2021 Numbers Showed Continued Strong Execution
Xeris Continues To Execute And Build Long-Term Value Potential
A Look At Recent Moves By Antares Pharma
Fennec Could See Upside If Pedmark Gets Approved
A Look At Unity's UBX1325 Phase 1 Results
OptiNose: Growing Sales Make The Current Market Cap Look Very Low
Harmony Biosciences Is Likely To Trade Higher As Wakix Sales Build
The Xeris-Strongbridge Merger Should Create Substantial Value For Shareholders
Zogenix's Current Price Seems Disconnected From A Strong Fintepla Launch
Updated OpRegen Data Looks Promising For Lineage
An Updated Look At Glaukos
Ocuphire's Low Market Cap Masks Significant Pipeline Potential
Sesen Bio: Long-Term And Short-Term Potential In Advance Of Its First PDUFA
Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business
Frequency Therapeutics: A Look At What's Next After A Disappointing Data Readout
Phathom Pharmaceuticals Could See Substantial Upside With 2 Upcoming Phase 3 Readouts
Aurinia Should Be A Long-Term Winner With Lupkynis Now On The Market
Strong Reproxalap Results Give Aldeyra A Good Balance Of Risk Versus Potential Reward
Yumanity: Speculative Upside Potential In Advance Of Multiple Near-Term Catalysts
Jelmyto And UGN-102 Will Likely Drive Strong Returns For UroGen Shareholders
Dicerna Is A Reasonably Priced Play In The Attractive RNAi Space
PAVmed's Esophageal Diagnostic Tools Should Create Strong Shareholder Value
Marketplace Contributors 2021 Top Ideas - Part 2
Rigel Still Looks Modestly Undervalued Despite The Recent Rally
G1 Therapeutics Likely Still Has Long-Term Upside Ahead Of The Trilaciclib PDUFA Date
2021 Roundtable: General Outlook - Biotech And Healthcare Investing
Provention Bio Could See Meaningful Upside Once Teplizumab Hits The Market
BioXcel Therapeutics Has Compelling Upside Potential In Advance Of Multiple Data Readouts
Kala Pharmaceuticals Should Have Limited Downside With Eysuvis Now Approved
Beyond Air Offers Compelling Value Heading Into Its First Potential Product Approval
Chiasma Trades At A Big Discount To Fair Value With Mycapssa On The Market
Eiger Looks Like A Solid Long-Term Play After Zokinvy's Approval
A Look Inside Unity Biotechnology's Transition To An Ophthalmology Company
Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex
Karyopharm Is Extremely Cheap After Recent Sell-Off
Zogenix Has A Wide Margin Of Safety After A 60% Sell-Off
Frequency Therapeutics Is An Interesting Speculative Play Ahead Of Phase 2 Results
The Sell-Off In Myovant Is Unjustified By Fundamentals
Ardelyx Is An Even Bigger Value After Recent Sell-Off
Evofem's Major Sell-Off Undervalues The Company's Long-Term Potential